{"groups":[{"description":"Paclitaxel 135 mg/m\\^2 intravenous (IV) over 1 hour; Gemcitabine 900 mg/m\\^2 IV over 90 minutes; Doxorubicin 40 mg/m\\^2 IV over 20 minutes; treatment may repeat every 2 weeks for up to nine courses. Subcutaneous Injection of Pegfilgrastim on day 1 or 2 of each course, after chemotherapy.","id":"FG000","title":"Gemcitabine, Paclitaxel and Doxorubicin"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"39"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"39"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"One patient withdrew from the study without receiving treatment.","recruitmentDetails":"Recruitment period: April 24, 2007 to November 10, 2011. All recruitment done within Community Clinical Oncology Programs (CCOP) medical clinics, specifically The University of Texas MD Anderson Cancer Center and the Ozarks Regional CCOP."}